Monoamine Oxidase is a Major Determinant of Redox Balance in Human Atrial Myocardium and is Associated With Postoperative Atrial Fibrillation

Ethan J. Anderson, PhD; Jimmy T. Efird, PhD; Stephen W. Davies, MD, MPH; Wesley T. O’Neal, MD, MPH; Timothy M. Darden, BS; Kathleen A. Thayne, MS; Lalage A. Katunga, BS; Linda C. Kindell, BSN, RN; T. Bruce Ferguson, MD; Curtis A. Anderson, MD; W. Randolph Chitwood, MD; Theodore C. Koutlas, MD; J. Mark Williams, MD; Evelio Rodriguez, MD; Alan P. Kypson, MD

Background—Onset of postoperative atrial fibrillation (POAF) is a common and costly complication of heart surgery despite major improvements in surgical technique and quality of patient care. The etiology of POAF, and the ability of clinicians to identify and therapeutically target high-risk patients, remains elusive.

Methods and Results—Myocardial tissue dissected from right atrial appendage (RAA) was obtained from 244 patients undergoing cardiac surgery. Reactive oxygen species (ROS) generation from multiple glutathione (GSHt) and its related enzymes GSH-peroxidase (GPx) and GSH-reductase (GR). Monoamine oxidase (MAO) and NADPH oxidase were observed to generate ROS at rates 10-fold greater than intact, coupled mitochondria. POAF risk was significantly associated with MAO activity (Quartile 1 [Q1]: adjusted relative risk [ARR]=1.0; Q2: ARR=1.8, 95% confidence interval [CI]=0.84 to 4.0; Q3: ARR=2.1, 95% CI=0.99 to 4.3; Q4: ARR=3.8, 95% CI=1.9 to 7.5; adjusted P_trend=0.009). In contrast, myocardial GSHt was inversely associated with POAF (Quartile 1 [Q1]: adjusted relative risk [ARR]=1.0; Q2: ARR=0.93, 95% confidence interval [CI]=0.60 to 1.4; Q3: ARR=0.62, 95% CI=0.36 to 1.1; Q4: ARR=0.56, 95% CI=0.34 to 0.93; adjusted P_trend=0.014). GPx also was significantly associated with POAF; however, a linear trend for risk was not observed across increasing levels of the enzyme. GR was not associated with POAF risk.

Conclusions—Our results show that MAO is an important determinant of redox balance in human atrial myocardium, and that this enzyme, in addition to GSHt and GPx, is associated with an increased risk for POAF. Further investigation is needed to validate MAO as a predictive biomarker for POAF, and to explore this enzyme’s potential role in arrhythmogenesis. (J Am Heart Assoc. 2014;3:e000713 doi: 10.1161/JAHA.113.000713)

Key Words: biomarkers • cardiopulmonary bypass • catecholamines • oxidative stress • post-operative atrial fibrillation • redox • tachyarrhythmias

Substantial improvements in patient outcomes following cardiac surgery have occurred over the past decade due to developments in technology and quality of care. However, there are a number of significant and costly post-operative complications associated with cardiac surgery, including post-operative atrial fibrillation (POAF). Even with anti-arrhythmic therapy and improvements in myocardial protection, the incidence of POAF remains at 25% to 40%.1 POAF typically occurs within the first 2 to 3 days after surgery and results in prolonged hospital length of stay. Patients with POAF have a doubled risk of cardiovascular mortality and a greater incidence of symptomatic hypotension, stroke, and other arrhythmias than patients without POAF.2,3 Findings from the Virginia Cardiac Surgery Quality Initiative, a state-wide cost analysis of all cardiac surgeries from 2004 to 2007, estimated that POAF increased total treatment costs by $12 000/patient.

Important gaps remain in understanding the etiology of POAF and why certain patients are more likely to have this complication. Systemic inflammation (generated primarily from extracorporeal circulation) and increased atrial reactive...
oxygen species (ROS) are believed to be causal factors. Both of these stressors potentially impair atrial contraction, disrupt myofibrillar energetics, and reduce the atrial effective refractory period. ROS-producing enzyme NADPH oxidase is up-regulated and oxidative stress is more persistent in patients with POAF than those that remain in sinus rhythm. The results of these studies support an association between ROS in human atrium and POAF.

Another factor contributing to POAF is the increased sympathetic tone and levels of circulating catecholamines following surgery. The importance of the association between circulating catecholamines and POAF is compounded by the intra- and post-operative use of high-dose catecholamines (eg, dopamine, dobutamine) as inotropic agents, a standard-of-care practice which continues despite the known association between inotropic support and POAF. The 2 primary enzymes responsible for metabolizing catecholamines are monoamine oxidase (MAO) and catechol O-methyltransferase (COMT). COMT is highly expressed in kidney and liver tissue, but expressed at low levels in the heart. MAO, which is present in the outer mitochondrial membrane, is responsible for oxidative deamination of catecholamines (eg, epinephrine, dopamine, serotonin) and the generation of H2O2, NH4+, and reactive aldehydes. Furthermore, this enzyme is involved in mood disorders and is the target of several pharmaceutical agents (MAO inhibitors) acting on this pathway. Recently, increased MAO activity has been observed to play a causal role in cardiac dysfunction during pressure overload due to oxidative stress.

In the current study, we sought to determine the overall contribution of MAO as a source of ROS in human myocardium. ROS generation by MAO, NADPH oxidase, and mitochondrial electron transport system (mito-ETS) was assessed in myocardial tissue dissected from right atrial appendage (RAA) obtained from patients undergoing cardiac surgery. Given the putative association between catecholamine overload, oxidative stress, and POAF, we hypothesized that MAO activity in the atrium and ROS produced by this enzyme may be associated with POAF. Additionally, we postulated that an association exists between POAF, myocardial glutathione (GSHt), and related enzymes GSH-peroxidase (GPx) and GSH-reductase (GR), since this is the primary antioxidant system present in mammalian cells and tissues.

**Methods**

**Patient Enrollment and Inclusion/Exclusion Criteria**

Approval for this study was granted by the Institutional Review Board of the Brody School of Medicine at East Carolina University. A total of 244 patients undergoing primary, non-emergent coronary artery bypass graft (CABG) or CABG/valve surgery between January 2009 and December 2012 were enrolled. Patients with severely enlarged atria (>4.0 cm diameter), history of arrhythmia, prior cardiac surgery, left ventricular ejection fraction (LVEF) <30%, and history of anti-arrhythmic medication were excluded from this study.

**Atrial Tissue Collection and Processing**

Following median sternotomy, but prior to institution of cardiopulmonary bypass, a sample of the right atrial appendage (RAA) was resected and immediately rinsed in ice-cold Buffer X. The sample was then blotted on gauze to remove excess buffer, trimmed of the epicardial layer, and frozen in liquid N2. This method ensured that all samples obtained were predominantly myocardium and rapidly processed and frozen (<90 seconds from time of removal) to minimize protein and mRNA degradation. In some cases viable atrial myocardium was transferred to the laboratory and used for preparation of permeabilized myofibers (PmFBs) and analysis of mitochondrial function.

**Permeabilized Fiber Preparation**

Portions of this technique have been described elsewhere, but have been adapted for application in human cardiac muscle and for specific measurements made in this study. After RAA tissue harvest, myocardium was removed and placed in ice-cold Buffer X, containing (in mmol/L): 7.23 K+EGTA, 2.77 CaK2EGTA, 20 Imidazole, 20 Taurine, 5.7 ATP, 14.3 PCR, 6.56 MgCl2, 6H2O, 50 MES; pH 7.1. Muscle was then cut into strips (4 mm × 2 to 3 mm wide and 2 hours). We have observed that PmFBs exhibit a very strong Ca2+-independent contraction that is temperature sensitive and can occur even at 4°C, therefore, 20 μmol/L Blebbistatin (Sigma-Aldrich) was added to the wash buffer, in addition to the respiration medium during experiments, to prevent contraction as previously described.
Measurement of Mitochondrial H₂O₂ Emission in Cardiac PmFBs

All mitochondrial H₂O₂ measurements were performed at 37°C. H₂O₂ coming from mito-ETS as a result of palmitoyl-l-carnitine, glutamate, and succinate oxidation was determined in PmFB’s with 100 μmol/L ADP, 5 mmol/L glucose, and 1 U/mL hexokinase present to keep the mitochondria in a permanent, submaximal phosphorylating state (i.e., most physiological).²⁰,²¹ H₂O₂ emission rate was determined in real time by continuous monitoring of Amplex Red oxidation in presence of horseradish peroxidase (1 U/mL) and superoxide dismutase (25 U/mL) using a spectrofluorometer (Photon Technology Instruments, Birmingham, NJ) equipped with a thermo-jacketed cuvette chamber.

MAO and NADPH Oxidase Activity

Myocardial samples frozen in liquid N₂ were homogenized in 10X (wt./vol) TEE buffer containing (in mmol/L: 10 Tris base, 1 EDTA, 1 EGTA, and 0.5% Tween-20), using a glass grinder (Kimble Chase). All enzyme activity and glutathione assays were performed on the same day as the protein extraction. We have empirically determined that glutathione and enzyme activity must be assessed immediately in protein extractions to obtain accurate results, and that freezing samples or keeping them at 4°C overnight will cause dramatic loss of content and activity. H₂O₂ generation from MAO and NADPH oxidase was determined in real time by continuous monitoring of Amplex Red oxidation in presence of horseradish peroxidase (1 U/mL) and superoxide dismutase (25 U/mL) using a spectrofluorometer (Horiba Jobin Yvon) equipped with a thermo-jacketed cuvette chamber maintained at 37°C. MAO activity was determined by continuous monitoring of clorgyline-sensitive H₂O₂ production supported by 1 mmol/L Tyramine or 2 μmol/L Norepinephrine, as previously described.²² NADPH oxidase activity was determined by continuous monitoring of apocynin-sensitive H₂O₂ production supported by 0.5 mmol/L NADPH.²³

GSHT, GPx, and GR Activity

All enzyme activity and glutathione assays were performed on the same day as the protein extraction. Total glutathione measurements were performed as described previously²⁴,²⁵ using a modified Tietze method.²⁶ GR activity in myocardial tissue was measured in TEE buffer containing 1 mmol/L GSSG and 0.5 mmol/L NADPH, where activity was calculated from the linear decrease in NADPH absorbance with time.²⁷ Glutathione peroxidase (GPx) activity was determined in TEE buffer containing 1 mmol/L GSH, 100 μU/mL glutathione reductase enzyme, 0.5 mmol/L NADPH. The reaction is initiated with a nominal amount of tert-Butyl-Hydroperoxide and the activity of GPx was calculated from the linear decrease in NADPH absorbance with time.²⁸

Determination of POAF

Postoperatively, patients’ heart rate and rhythm were continuously monitored with telemetry until discharge. POAF was defined by a sustained episode of atrial fibrillation lasting ≥1 minute, or for any length of time requiring intervention for hemodynamic compromise.

Statistical Analysis

Categorical variables were reported as frequency and percentage while continuous variables were reported as mean±standard deviation, median, and interquartile range. Variables not previously categorized were divided into quartiles prior to statistical analysis. Quartile categorization is advantageous because it limits the influence of outliers and allows for the assessment of trend across categories.

Statistical significance of group comparisons for categorical variables was determined using Fisher exact and chi-square (χ²) procedures and for continuous variables was determined using the Deuchler-Wilcoxon method. Relative risk and 95% confidence intervals were computed using log-binomial or robust Poisson regression. P values for trend were computed using a likelihood ratio test (or score test when convergence was not achieved). Assays were performed using a missing by design sampling strategy. The iterative expectation-maximization (EM) algorithm was used to impute missing values.²⁹–³¹ The relative imputation efficiency ranged from 96% to 99% (variance inflation: MAO=0.38, GSHT=0.02, GPx=0.15, GR=0.54; fraction missing information: MAO=0.29, GSHT=0.02, GPx=0.14, GR=0.37). Patients with and without missing data did not differ by key demographic characteristics (i.e., age, sex, race; Hochberg adjusted P>0.05).³² Furthermore, a complete-case analysis was performed and it did not substantively change the results of the study. The multivariable models included variables that have been previously reported to be associated with POAF, regardless of their statistical significance in our dataset. These included age, sex, race, diabetes, hypertension, ACEI use, ARB use, statin use, and CPBT.³³–³⁶ Statistical significance was defined as P<0.05. SAS Version 9.3 was used for all analyses.
Results
Analysis of Major ROS Sources in Human Atrial Myocardium

An assessment of 3 major ROS sources in atrial myocardium was performed from RAA biopsies of 12 individual patients (demographic and clinical characteristics of these 12 patients is provided in Table 1). Rates of H₂O₂ production in the myocardial tissue homogenate was confirmed to be derived from MAO and NADPH oxidase based on the sensitivity to their inhibitors clorgyline and apocynin, respectively (Figure 1A). H₂O₂ production derived from the mito-ETS was driven by oxidation of substrates as they were individually titrated into the respiration medium containing the PmFBs (Figure 1A). Total rates of H₂O₂ production from these 3 sources were individually quantified and combined within each of the 12 patients (Figure 1B). The rate of H₂O₂ originating from mito-ETS was determined to be at least 10-fold lower than either MAO or NADPH oxidase alone. As previously reported by our group, diabetic patients had significantly higher rates of H₂O₂ from mito-ETS compared with non-diabetic patients.²⁰,²¹

Patient Characteristics, Biochemical Markers, and Relationship to POAF

A total of 80 (33%) patients developed POAF. Patients with POAF were older and presented more frequently with hypertension than those without POAF (Table 2). Additionally, they experienced longer CPBT. Mean MAO levels were significantly higher among patients with POAF (P<0.0001) and a linear trend across quartile levels was observed (P_trend<0.0001), with the incidence of POAF being the highest in quartile 4 compared with quartile 1 (Figure 2). POAF was not associated with GSHt, GPx, and GR (Figures 3 and 4B and 4C) in the univariable analysis. In multivariable analysis, MAO remained statistically significant after adjusting for sex, race, diabetes, hypertension, ACEI/ARB use, statin use, and CPBT (P_trend=0.009, Table 3). A statistically significant linear trend also was observed for GSHt in multivariable analysis (P_trend=0.014).

Discussion

Several reports have documented the inverse association of POAF and β-blocker use, illustrating the underlying etiologic role of catecholamines and excessive sympathetic discharge.³⁷,³⁸ Others have used prophylactic amiodarone,³⁹ sotalol,⁴⁰ magnesium,⁴¹ and statins,⁴² all of which were successful at reducing the incidence of POAF to varying degrees; however, all patients were treated regardless of POAF status. These studies illustrate the importance of investigating biological factors that may predispose patients to POAF.

The findings of this study demonstrate for the first time that MAO is a major source of ROS in human atrial myocardium, and its activity varies across a 50-fold range among patients. It also provides evidence that atrial MAO activity serves as an independent predictor of POAF and lends further support to the current theory that redox imbalance (ie, oxidative stress) in atrial myocardium is a significant factor in the etiology of POAF, particularly with respect to our

Table 1. Clinical and demographic information specific for patients in Figure 1.

| Pt # | Age | Sex | Race | Diabetes | HbA1c | HF | POAF | Tobacco | COPD | Prior MI | HTN |
|------|-----|-----|------|----------|-------|----|------|---------|------|----------|-----|
| 1    | 79  | F   | AA   | Y        | 6.9   | N  | N    | N       | N    | N        | Y   |
| 2    | 63  | F   | C    | Y        | 10    | N  | N    | Y       | Y    | Y        | Y   |
| 3    | 67  | F   | AA   | Y        | 7.2   | Y  | Y    | Y       | N    | N        | Y   |
| 4    | 62  | F   | AA   | N        | –     | N  | N    | N       | N    | N        | Y   |
| 5    | 60  | F   | C    | Y        | 9.2   | N  | N    | N       | N    | N        | Y   |
| 6    | 69  | F   | AA   | N        | –     | N  | N    | Y       | N    | N        | Y   |
| 7    | 47  | M   | C    | N        | –     | N  | N    | N       | N    | N        | Y   |
| 8    | 56  | M   | C    | N        | –     | N  | N    | N       | N    | N        | Y   |
| 9    | 52  | M   | AA   | N        | –     | N  | N    | Y       | N    | N        | Y   |
| 10   | 44  | M   | C    | N        | –     | N  | N    | Y       | N    | Y        | Y   |
| 11   | 58  | M   | C    | N        | –     | N  | Y    | N       | N    | N        | Y   |
| 12   | 52  | M   | C    | Y        | 8.9   | N  | Y    | N       | Y    | Y        | Y   |

*Absent values (–) for glycated hemoglobin (HbA1c) indicate that levels were within normal range (4.5% to 5.9%) for that particular patient (Pt). AA indicates African-American; C, Caucasian; COPD, history of chronic obstructive pulmonary disease; HF, history of heart failure; HTN, history of hypertension; MI, myocardial infarction; POAF, post-operative atrial fibrillation.*

DOI: 10.1161/JAHA.113.000713
myocardial GSHt-related data. Furthermore, the results collectively integrate a number of perioperative factors known to contribute to the etiology of POAF (eg, catecholamine overload and oxidative stress).

Investigation into the etiology of POAF has largely focused on systemic inflammation and oxidative stress in the postoperative period. Redox modifications of ion channels and proteins have been observed to directly impact cardiomyocyte electrical\textsuperscript{43,44} and mechanical\textsuperscript{45} function and has been implicated in the early stages of electrical remodeling which accompanies the onset of AF.\textsuperscript{46} Inflammation is interconnected with myocardial oxidative stress.\textsuperscript{4,5} Circulating cytokines and electrophilic lipids increase strain on antioxidant mechanisms in cardiomyocytes, a system already burdened with buffering oxidants originating from endogenous sources (eg, MAO, NADPH oxidase, and mitochondria) (Figure 1). The most important buffer of ROS in mammalian cells and tissue is GSH, which is converted to its oxidized form (GSSG) by GPx in the presence of hydroperoxides, and recycled back to its reduced form by NADPH-dependent GR. The GSH/GSSG (reduced/oxidized) redox couple is considered to be the key indicator of cellular redox environment.\textsuperscript{47} Also important to cellular/tissue redox environment is total amount of GSH (GSHt), defined as the additive amount of free GSH and GSSG. A decrease in GSHt potentially increases a cell’s susceptibility to the adverse outcomes associated with oxidative stress (eg, oxidative modifications of proteins, lipids, and DNA).

Our findings that GSHt and GPx are inversely correlated with POAF (Figures 3 and 4) suggests that a greater antioxidant capacity should lead to lower incidence of POAF because of a greater buffering of ROS during the postoperative period. Clinical trials have shown that anti-inflammatory/antioxidant therapies lead to a decreased incidence of POAF.\textsuperscript{48,49} For example, preoperative n-3 polyunsaturated fatty acids (PUFAs) and concentrated antioxidant supplementation have been observed to enhance anti-inflammatory/antioxidant capacity in atrial myocardium at the cellular level.\textsuperscript{50} A follow-up clinical trial with this therapy led to a substantial decrease in POAF.\textsuperscript{51} Use of n-3 PUFAs alone as prophylactic therapy to mitigate incidence of POAF has led to mixed results. For example, the omega-3 fatty acids for prevention of postoperative atrial fibrillation (OPERA) trial showed that a very high dose (8 to 10 g/day) of n-3 PUFAs for 2 to 3 days preoperatively did not reduce the incidence of POAF.\textsuperscript{52} Nevertheless, use of n-3 PUFAs as prophylactic therapy for arrhythmia and other cardiovascular diseases remains a viable therapeutic option due to the pleiotropic, beneficial effects of these fatty acids in the heart.

Mitochondria, as a consequence of their intracellular volume and density, are considered the predominant source of intracellular ROS in myocardium.\textsuperscript{53} However, the total ROS that escapes (ie, ROS emission) from the mitochondria is minimized by the reducing environment within the matrix of this organelle in addition to its redox enzyme network.\textsuperscript{54,55}

**Figure 1.** Comparative analysis of major ROS sources in human atrial myocardium. A, Representative H\textsubscript{2}O\textsubscript{2} production traces from NADPH oxidase (blue), MAO (red), and mito-ETS (black dash) in RAA tissue obtained from one individual patient. PmFBs were used for determining H\textsubscript{2}O\textsubscript{2} from mito-ETS, while homogenate was used for NADPH oxidase and MAO. Substrates were added to cuvette where indicated. Apocynin and Clorgyline are administered where indicated to confirm the source of H\textsubscript{2}O\textsubscript{2} production to be NADPH oxidase and MAO, respectively. In (B) are the quantified rates from each of these 3 sources in RAA tissue obtained from 12 individual patients. MAO indicates monoamine oxidase; mito-ETS, mitochondrial electron transport system; NADPH, \textbeta-Nicotinamide adenine dinucleotide phosphate hydrate; PmFBs, permeabilized myofibers; RAA, right atrial appendage; ROS, reactive oxygen species.
Table 2. Patient and Operative Characteristics Stratified by Postoperative Rhythm Class and Univariable Relative Risk for POAF (N=244)

| Variables                  | POAF n (%) | POSR n (%) | P Value | Univariable RR (95% CI) |
|----------------------------|------------|------------|---------|-------------------------|
| Overall                    | 80 (33)    | 164 (67)   | —       | —                       |
| Demographics/comorbidities |            |            |         |                         |
| Age                        |            |            |         |                         |
| Mean±SD                    | 66±8.7     | 62±10      | 0.0019  | —                       |
| Median (IQR)               | 67 (14)    | 62 (16)    |         |                         |
| Q1 (56)                    | 10 (13)    | 54 (33)    | 0.0045  | Referent                |
| Q2 (56 to 64)              | 20 (25)    | 39 (24)    | 2.2 (1.1 to 4.2) |                         |
| Q3 (64 to 71)              | 23 (29)    | 37 (23)    | 2.5 (1.3 to 4.7) |                         |
| Q4 (>71)                   | 27 (34)    | 34 (21)    | 2.8 (1.5 to 5.3) |                         |
| Ptrend                     | —          | —          | 0.0008  |                         |
| Sex                        |            |            | 0.19    |                         |
| Female                     | 14 (18)    | 41 (25)    |         | Referent                |
| Male                       | 66 (83)    | 123 (75)   | 1.4 (0.84 to 2.2) |                     |
| Race                       |            |            | 0.27    |                         |
| White                      | 69 (86)    | 132 (80)   |         | Referent                |
| Black                      | 11 (14)    | 32 (20)    | 1.3 (0.78 to 2.3) |                        |
| Diabetes                   |            |            | 0.096   |                         |
| No                         | 50 (63)    | 84 (51)    |         | Referent                |
| Yes                        | 30 (38)    | 80 (49)    | 0.73 (0.50 to 1.06) |                     |
| Hypertension               |            |            | 0.019   |                         |
| No                         | 7 (9)      | 34 (21)    |         | Referent                |
| Yes                        | 73 (91)    | 130 (79)   | 2.1 (1.05 to 4.2) |                     |
| BMI*                       |            |            | 0.74    |                         |
| Mean±SD                    | 30±5.7     | 30±6.2     |         | —                       |
| Median (IQR)               | 30 (7.4)   | 30 (7.2)   |         |                         |
| Q1 (≤26)                   | 23 (29)    | 39 (24)    | 0.69    | Referent                |
| Q2 (26 to 30)              | 17 (22)    | 43 (26)    | 0.76 (0.46 to 1.3) |                     |
| Q3 (30 to 33)              | 22 (27)    | 40 (25)    | 0.96 (0.60 to 1.5) |                         |
| Q4 (>33)                   | 18 (23)    | 42 (26)    | 0.81 (0.49 to 1.3) |                         |
| Ptrend                     | —          | —          | 0.69    |                         |
| Smoking                    |            |            | 0.18    |                         |
| No                         | 59 (74)    | 107 (65)   |         | Referent                |
| Yes                        | 21 (26)    | 57 (35)    | 0.76 (0.50 to 1.2) |                     |
| COPD                       |            |            | 0.14    |                         |
| No                         | 60 (75)    | 136 (83)   |         | Referent                |
| Yes                        | 20 (25)    | 28 (17)    | 1.4 (0.92 to 2.02) |                     |
| Prior stroke               |            |            | 0.68    |                         |
| No                         | 74 (93)    | 154 (94)   |         | Referent                |
| Yes                        | 6 (8)      | 10 (6)     | 1.2 (0.60 to 2.2) |                     |

Continued
Table 2. Continued

| Variables         | POAF n (%) | POSR n (%) | P Value | Unvariable RR (95% CI) |
|-------------------|------------|------------|---------|-----------------------|
| Prior MI          |            |            |         |                       |
| No                | 45 (56)    | 75 (46)    | 0.12    | Referent              |
| Yes               | 35 (44)    | 89 (54)    | 0.75    | (0.52 to 1.08)        |
| HF                |            |            |         |                       |
| No                | 79 (99)    | 155 (95)   | 0.089†  | Referent              |
| Yes               | 1 (1)      | 9 (5)      | 0.30    | (0.046 to 1.9)        |
| Ejection fraction*|            |            |         |                       |
| Mean±SD           | 54±11      | 53±14      | 0.30    | —                     |
| Median (IQR)      | 58 (10)    | 54 (15)    |         |                       |
| Q1 (≤48)          | 17 (22)    | 52 (32)    | 0.066   | Referent              |
| Q2 (48 to 55)     | 19 (24)    | 42 (26)    | 1.3     | (0.72 to 2.2)         |
| Q3 (55 to 62)     | 25 (31)    | 28 (17)    | 1.9     | (1.2 to 3.2)          |
| Q4 (>62)          | 19 (24)    | 42 (26)    | 1.3     | (0.72 to 2.2)         |
| R_trend = 0.15    |            |            |         |                       |
| CAD severity*     |            |            |         |                       |
| 1-vessel          | 3 (4)      | 11 (7)     | 0.20    | Referent              |
| 2-vessel          | 15 (19)    | 44 (27)    | 1.2     | (0.40 to 3.5)         |
| 3-vessel          | 62 (77)    | 109 (67)   | 1.7     | (0.61 to 4.7)         |
| R_trend = 0.079   |            |            |         |                       |
| Left main disease |            |            |         |                       |
| No                | 65 (81)    | 135 (82)   | 0.84    | Referent              |
| Yes               | 15 (19)    | 29 (18)    | 1.0     | (0.66 to 1.7)         |
| Preoperative Medications |  |  |  |  |
| Beta-blockers     |            |            |         |                       |
| No                | 12 (15)    | 28 (17)    | 0.68    | Referent              |
| Yes               | 68 (85)    | 136 (83)   | 1.1     | (0.67 to 1.9)         |
| ACEI/ARBs         |            |            |         |                       |
| No                | 70 (88)    | 128 (78)   | 0.076   | Referent              |
| Yes               | 10 (13)    | 36 (22)    | 0.61    | (0.34 to 1.1)         |
| Statins           |            |            |         |                       |
| No                | 18 (23)    | 33 (20)    | 0.67    | Referent              |
| Yes               | 62 (78)    | 131 (80)   | 0.91    | (0.60 to 1.4)         |
| Intraoperative Characteristics |  |  |  |  |
| CPB               |            |            |         |                       |
| No                | 3 (4)      | 10 (6)     | 0.44    | Referent              |
| Yes               | 77 (96)    | 154 (94)   | 1.4     | (0.53 to 4.0)         |
| CPBT (min)        |            |            |         |                       |
| Mean±SD           | 120±33     | 110±37     | 0.012   | —                     |
| Median (IQR)      | 115 (37)   | 104 (48)   |         |                       |
| Q1 (≤87)          | 9 (12)     | 49 (32)    | 0.0092  | Referent              |
| Q2 (87 to 108)    | 22 (29)    | 37 (24)    | 2.4     | (1.2 to 4.8)          |
| Q3 (108 to 134)   | 26 (34)    | 35 (23)    | 2.7     | (1.4 to 5.4)          |
| Q4 (>134)         | 20 (26)    | 33 (21)    | 2.4     | (1.2 to 4.9)          |
This potentially explains our observation that H₂O₂ originating from mito-ETS was markedly lower than from either MAO or NADPH oxidase alone (Figure 1). ROS derived from NADPH oxidase in atrial myocardium, and downstream ROS (eg, peroxynitrite and reactive aldehydes) have been shown to be significantly correlated with POAF.⁶⁻⁷ Our findings further support the clinical importance of ROS-generating enzymes in atrial tissue and provide novel evidence that ROS derived from MAO may be a key determinant of myocardial redox balance in the postoperative period.
While MAO is an enzyme physically tethered to the outer mitochondrial membrane, MAO-derived ROS typically is not considered to be “mitochondrial ROS.” Our findings support a paradigm shift in the way this enzyme is viewed within the context of cellular redox balance. The wide range in MAO activity (~50-fold) across patients is a significant feature of our findings (Figure 2). Theoretically, the expression and activity of cardiac MAO should reflect sympathetic tone; however, there is considerable variation in promoter activity and transcriptional control of MAO genes in humans. This may explain the underlying variation in enzyme activity seen in our patient cohort. Conceivably, high levels of catecholamines in the postoperative period may lead to increased concentrations inside cardiomyocytes by neuronal monoamine transporters in the sarcolemmal membrane. Thus, in patients where MAO activity is high (Q3 and Q4, Figure 2), MAO-derived ROS may in turn be increased, leading to oxidative stress and potentially triggering POAF. In the remodeled myocardium, where fibrosis and altered ion channel expression are present, oxidative stress and inflammation only comprise a portion of the arrhythmogenic substrate. Accordingly,

| Models | ARR 95% CI |
|--------|------------|
| MAO†   |            |
| Q1 (≤1344) | Referent   |
| Q2 (1344 to 2035) | 1.8 (0.83 to 4.0) |
| Q3 (2035 to 2820) | 2.1 (0.99 to 4.3) |
| Q4 (>2820) | 3.8 (1.9 to 7.5) |
| $\beta_{\text{trend}}$=0.009 |
| GSH†   |            |
| Q1 (≤16) | Referent   |
| Q2 (16 to 20) | 0.93 (0.60 to 1.4) |
| Q3 (20 to 23) | 0.62 (0.36 to 1.1) |
| Q4 (>23) | 0.56 (0.34 to 0.93) |
| $\beta_{\text{trend}}$=0.014 |
| GPX†   |            |
| Q1 (≤12) | Referent   |
| Q2 (12 to 17) | 1.9 (1.1 to 3.3) |
| Q3 (17 to 21) | 2.4 (1.4 to 4.2) |
| Q4 (>21) | 1.4 (0.75 to 2.7) |
| $\beta_{\text{trend}}$=0.21 |

ARR indicates adjusted relative risk; CI, confidence interval; GPX, glutathione peroxidase; GSH, glutathione; MAO, monoamine oxidase; POAF, postoperative atrial fibrillation; Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile.

Figure 2. MAO activity in atrial myocardium and incidence of POAF. All rates of MAO activity from entire cohort of patients recruited for this study are shown (1 circle=1 patient). Quartiles of pooled data were generated, and univariable analysis performed with POAF as the outcome variable using Poisson regression. Each quartile is delineated with color shading to illustrate the risk of POAF within that particular quartile (Green深入了解15%, Yellow深入了解15% to 30%, Orange深入了解30% to 40%, Red深入了解60%). Within each quartile, POAF incidence=number of patients in that particular quartile experiencing POAF. RR=relative risk, with 95% confidence interval (CI). MAO indicates monoamine oxidase; POAF, post-operative atrial fibrillation.

Figure 3. Total GSH (GSHt) in atrial myocardium and incidence of POAF. Data shown in this figure is GSHt for the entire cohort of patients recruited for this study. Quartiles of pooled data were generated, and univariable analysis performed with POAF as the outcome variable using Poisson regression. Each quartile is delineated with color shading to illustrate the risk of POAF within that particular quartile (Green深入了解15%, Yellow深入了解15% to 30%, Orange深入了解30% to 40%, Red深入了解60%). Within each quartile, POAF incidence=number of patients in that particular quartile experiencing POAF. RR=relative risk, with 95% confidence interval (CI). GSHt indicates total glutathione; POAF, post-operative atrial fibrillation.
therapeutic strategies to mitigate POAF need to account for all of these possibilities.

Our study is strengthened by its prospective and systematic data collection. Additionally, biomarkers were obtained from myocardial tissue and reflect local cardiac versus serum levels. However, several limitations should be noted. Only the right atrial myocardium was collected in this study, and this may not be the best anatomic site to represent cardiac remodeling and oxidative stress pathways in the heart, given the known importance of the left atrium as a site of arrhythmogenesis. Moreover, studies have shown that as the pathology of AF progresses, a gradient of cardiac remodeling occurs starting in the left atrium and ending in the right atrium. The temporality and spatial heterogeneity of this remodeling may be missed by capturing only the right atrium. However, because this patient cohort did not have any history of arrhythmia or cardiac surgery, it is unlikely that any remodeling that may exist is due to atrial arrhythmia.

Saturating concentrations of substrate (eg, Tyramine, NADPH, glutamate, etc) were used to measure enzyme activities in our assays. This rarely exists in vivo. However, the use of saturating substrate concentration was appropriate because the objective was to compare the maximal capacity for ROS generation and scavenging from myocardial enzymes.

Biopsies were obtained at a single point in time; therefore it was not possible to determine the temporality of biomarker levels. Limited longitudinal information was available in our dataset. We were unable to determine the dose, duration, and frequency of β-blocker use prior to surgery for each patient. Furthermore, our sample size was small and residual confounding may have been present.

In conclusion, our study suggests that MAO is a major ROS source in human atrial myocardium and is an important biomarker for POAF, providing clinicians with the ability to predict which patients are predisposed to this postoperative complication. Advanced knowledge of POAF risk will enable appropriate prophylactic treatment to be initiated at the time of surgery, potentially leading to reduced hospital stay and healthcare costs associated with this complication. Additional investigation is needed to elucidate the role of MAO in arrhythmogenesis and to validate our findings in other populations and disease processes.

**Acknowledgments**

The authors would like to specifically thank the research nurses and clinical staff at ECHI for their assistance with informed consent and study coordination.
Sources of Funding
This research was supported by grant R21HL098780 (Anderson, Kypon) from National Institutes of Health.

Disclosures
None.

References

1. Mathew JP, Fortes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, Barash PG, Hsu PH, Mangan DT. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004;291:1720–1729.

2. Ahlsson A, Fensxurud E, Bodin L, Englund A. Postoperative atrial fibrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a doubled cardiovascular mortality. Eur J Cardiothorac Surg. 2010;37:1353–1359.

3. El-Chami MF, Kilgo P, Thourani V, Lattouf OM, Delurgio DB, Guyton RA, Leon AR, Pusakas JD. New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft. J Am Coll Cardiol. 2010;55:1370–1376.

4. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108:3006–3010.

5. Ishi Y, Schuessler RB, Gaynor SL, Yamada K, Fuji FS, Boineau JP, Damiano RJ Jr. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and fibrillation. Circulation. 2005;111:2881–2888.

6. Kim YM, Kattch H, Nathatunga C, Miserral MS, Damiano TJ Jr. Inflammation of atrium during cardiac surgery is associated with inhomogeneity of atrial conduction and fibrillation. J Cardiothorac Surg. 2005;10:67–74.

7. Antoniades C, Demosthenous M, Reilly S, Margaritis M, Zhang MH, Antonopoulos C, Demosthenous K, Dougenis D, Apostolakis E. Prognostic factors of atrial fibrillation in patients undergoing aorto-coronary bypass surgery. Current trends and impact on hospital resources. Ann Thorac Surg. 2013;95:1650–1656.

8. Ramlawi B, Otu H, Mieno S, Boodhwani M, Sodha NR, Clements RT, Bianchi WS. Atrial fibrillation following elective coronary artery bypass grafting: the impact of race and risk factors on incidence of atrial fibrillation. JAMA. 2009;301:1898–1906.

9. Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, VanderVliet M, Collins JJ Jr, Cohn LH, Burstein HR. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation. 1996;94:390–397.

10. Mathew JP, Parks R, Savino JS, Friedman AS, Koch C, Mangan DT, Browner WS. Atrial fibrillation following coronary artery bypass graft surgery: predictors, outcomes, and resource utilization. Multicenter Study of Perioperative Ischemia Research Group. JAMA. 1996;276:300–306.

11. Koletsis EN, Prokakis C, Crockett JR, Dedeilias P, Panagiotou M, Panagopoulos N, Anastasiou N, Dougenis D, Apostolakis E. Prognostic factors of atrial fibrillation following elective coronary artery bypass grafting: the impact of quantitative intraoperative myocardial ischemia. J Cardiothorac Surg. 2011;6:127.

12. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane monoamine oxidases. Biochemistry. 2009;48:4220–4230.

13. Youdim MB, Finberg JP. New directions in monoamine oxidase A and B selective inhibitors and substrates. Biochem Pharmacol. 1991;41:155–162.

14. Edmondson DE, Binda C, Wang J, Upadhyak AY, Mattevi A. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidase. Biochemistry. 2009;48:4220–4230.

15. Kaluderovic N, Takimoto E, Nagayama T, Feng N, Lai EW, Bedja D, Chen K, Gabrielson KL, Blakely RD, Shih JC, Pacak K, Kass DA, Di Lisa F, Paolocci N. Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ Res. 2010;106:192–202.

16. Kaluderovic N, Carpi A, Nagayama T, Sivakumar V, Zhu G, Lai EW, Bedja D, De Mario A, Chen K, Gabrielson KL, Lindsey ML, Pacak K, Takimoto E, Shih JC, Kass DA, Di Lisa F, Paolocci N. Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. Antioxid Redox Signal. 2014;20:267–280. doi: 10.1089/ars.2012.4616. Epub May 22, 2013.

17. Anderson EJ, Yamazaki H, Neuf D. Induction of endogenous uncoupling protein 3 suppresses mitochondrial oxygen emission during fatty acid-supported respiration. J Biol Chem. 2007;282:31257–31266.

18. Kane DA, Lin CT, Anderson EJ, Kwak HB, Cox JH, Brophy PM, Hickner RC, Neuf D, Cortright RN. Progesterone increases skeletal muscle mitochondrial H2O2 emission in normogonadal women. Am J Physiol Endocrinol Metab. 2011;300:E528–E535.

19. Perry CG, Kane DA, Lin CT, Kozy R, Cathey BL, Lark DS, Kane CL, Brophy PM, Gavin TP, Anderson EJ, Neuf D. Inhibiting myosin-ATPase reveals a dynamic range of mitochondrial respiratory control in skeletal muscle. Biochem J. 2011;437:215–222.

20. Anderson EJ, Kypon AP, Rodriguez E, Anderson CA, Leth EJ, Neuf D. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol. 2009;54:1891–1898.

21. Anderson EJ, Rodriguez E, Anderson CA, Thayne K, Chitwood WR, Kypon AP. Increased propensity for cell death in diabetic human heart is mediated by mitochondrial-dependent pathways. Am J Physiol Heart Circ Physiol. 2011;300: H118–H124.

22. Hauptmann N, Grimes J, Shih JC, Cadenas E. The metabolism of tyramine by monoamine oxidase A/B causes oxidative damage to mitochondrial DNA. Arch Biochem Biophys. 1996;335:295–304.

23. La Favor JD, Anderson EJ, Dawkins JT, Hickner RC, Wingard C. Exercise prevents Western-diet associated erectile dysfunction and coronary artery endothelial dysfunction: response to acute apocynin and sepiapterin treatment. Am J Physiol Regul Integr Comp Physiol. 2013;305:R423–R434. doi: 10.1152/ajpregu.00049.2013. Epub June 12, 2013.

24. Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, Price JW III, Kang L, Rabinovitch PS, Szeto HH, Houmard JA, Cortright RN, Wasserman DH, Neuf D. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest. 2009;119:573–581. doi: 10.1172/JCI37048. Epub February 2, 2009.

25. Anderson EJ, Thayne K, Harris M, Carraway K, Shaih SR. Aldosterone and up-regulation of Nrf2-mediated antioxidant systems accompany functional adaptations in cardiac mitochondria from mice fed n-3 polyunsaturated fatty acids. Biochem J. 2012;441:359–366.

26. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969;27:502–522.

27. Carberg I, Mannervik B. Glutathione reductase. Methods Enzymol. 1985;113:484–490.

28. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70:158–169.

29. Dempster AP, Laird NM, Rubín DB. Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc Series B Stat Methodol. 1977;39:1–38.

30. Ware JH, Harrington D, Hunter DJ, D’Agostino R. Missing data. N Engl J Med. 2012;367:1353–1354.

31. Little RJ, D’Agostino R, Cohen ML, Dickerson K, Emerson SS, Farrar JT, Frangakis C, Hogan JW, Molenberghs G, Murphy SA, Neaton JD, Rotnitzky A, Scharfstein D, Shih WJ, Siegel JP, Stern H. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367:1355–1360.

32. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800–802.

33. Rienstra M, McManus DD, Benjamin EJ. Novel risk factors for atrial fibrillation: useful for risk prediction and clinical decision making? Circulation. 2012;125:e941–e946.

34. Rossia M, Dziuba M, Chudzik M, Cynkawicz B, Bartczak K, Drozdz J, Wranicz. J, Ellinor PT, Benjamin EJ. Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. Circulation. 2011;124:1982–1993.

35. Gbadede TD, Okahor F, Darbar D. Differential impact of race and risk factors on incidence of atrial fibrillation. Am Heart J. 2011;162:31–37.

36. Coleman CI, Perskerson KA, Gilispée EL, Kluger J, Gallagher R, Horowitz S, White CM. Impact of prophylactic beta-blockade on post-cardiothoracic surgery length of stay and atrial fibrillation. Annu Pharmacother. 2004;38:2012–2016.
38. Connolly SJ, Cybulsky I, Lamy A, Roberts RS, O’Brien B, Carroll S, Crystal E, Thorpe KE, Gent M. Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the beta-Blocker Length Of Stay (BLOS) study. *Am Heart J.* 2003;145:226–232.

39. Mitchell LB, Exner DV, Wyse DG, Connolly CJ, Prystai GD, Bayes AJ, Kidd WT, Kieser T, Burgess JJ, Ferland A, MacAdams CL, Maitland A. Prophylactic oral amiodarone for the prevention of arrhythmias that begin early after revascularization, valve replacement, or repair: PAPABEAR: a randomized controlled trial. *JAMA.* 2005;294:3093–3100.

40. Nyström U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. Oral sotalol reduces the incidence of atrial fibrillation after coronary artery bypass surgery. *Thorac Cardiovasc Surg.* 1993;41:34–37.

41. Miller S, Crystal E, Garfinkle M, Lau C, Lashevsky I, Connolly SJ. Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis. *Heart.* 2005;91:618–623.

42. Patti G, Chello M, Candura D, Pasceri V, D’Ambrosio A, Covino E, Di Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After cardiac surgery) study. *Circulation.* 2006;114:1455–1461.

43. Adamson PB, Barr RC, Callans DJ, Chen PS, Lathrop DA, Makielski JC, Nerbonne JM, Nuss HB, Olgin JE, Przywara DA, Rosen MR, Rozanski GJ, Spach MS, Yamada KA. The perplexing complexity of cardiac arrhythmias: beyond electrical remodeling. *Heart Rhythm.* 2005;2:650–659.

44. Van Wagoner DR. Redox modulation of cardiac electrical activity. *J Cardiovasc Electrophysiol.* 2001;12:183–184.

45. Ukai T, Cheng CP, Tachibana H, Igawa A, Zhang ZS, Cheng Hj, Little WC. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. *Circulation.* 2001;103:750–755.

46. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. *Cardiovasc Res.* 2002;54:230–246.

47. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. *Free Radic Biol Med.* 2001;30:1191–1212.

48. Pepe S, Leong JY, Van der Merwe J, Marasco SF, Hadji A, Lymphury R, Perkins A, Rosenfeldt FL. Targeting oxidative stress in surgery: effects of ageing and therapy. *Exp Gerontol.* 2008;43:653–657.

49. Ozaydın M, Peker O, Erdogan D, Kapan S, Turker Y, Varol E, Ozguner F, Dogan A, Ibririm E. N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study. *Eur Heart J.* 2008;29:625–631.

50. Castillo R, Rodrigo R, Perez F, Cereceda M, Asenjo R, Zamorano J, Navarrete R, Villalibetia E, Sanz J, Baeza C, Aguayo R. Antioxidant therapy reduces oxidative and inflammatory tissue damage in patients subjected to cardiac surgery with extracorporeal circulation. *Basic Clin Pharmacol Toxicol.* 2011;108:256–262.

51. Rodrigo R, Korantzopoulos P, Cereceda M, Asenjo R, Zamorano J, Villalibetia E, Baeza C, Aguayo R, Castillo R, Carrasco R, Gormaz JG. A randomized controlled trial to prevent postoperative atrial fibrillation by antioxidant reinforcement. *J Am Coll Cardiol.* 2013;62:1457–1465. doi: 10.1016/j.jacc.2013.07.014. Epub July 31, 2013.

52. Mozaffarian D, Marchiolii R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O’Gara PT, Page RL, Tavazzi L, and Tognoni G. Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. *JAMA.* 2012;308:2001–2011.

53. Jezek P, Hlavata L. Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organam. *Int J Biochem Cell Biol.* 2005;37:2478–2503.

54. Palace V, Kumar D, Hill MF, Klaper N, Singal PK. Regional differences in non-enzymatic antioxidants in the heart under control and oxidative stress conditions. *J Mol Cell Cardiol.* 1999;31:193–202.

55. Fisher-Wellman KH, Mattox TA, Thayne K, Katunga LA, La Favor JD, Neuber PD, Hickner RC, Wingard CJ, Anderson EJ. Novel role for thioredoxin reductase-2 in mitochondrial redox adaptations to obesogenic diet and exercise in heart and skeletal muscle. *J Physiol.* 2013;591:12471–12486.

56. Holschneider DPS, Shih JC. Monooamine Oxidase: Basic and Clinical Perspectives. Vol 4. New York, NY: Raven Press; 2000.

57. De Jong AM, Maass AH, Overdorff-Maass SU, Van Veldhuisen DJ, Van Gilst WH, Van Gelder IC. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. *Cardiovasc Res.* 2011;89:754–765.